We are live on
!
Find out more
VA
Verdad Advisers Portfolio holdings
AUM
$104M
This Fund
S&P 500
This Quarter
Est. Return
+21.07%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$104M
AUM Growth
+$15.6M
(+18%)
Cap. Flow
+$3.28M
Cap. Flow
% of AUM
3.14%
Top 10 Holdings %
Top 10 Hldgs %
18.12%
Holding
276
New
97
Increased
59
Reduced
42
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.13M |
| 2 |
Protara Therapeutics
TARA
|
+$1.49M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$1.44M |
| 4 |
Tyra Biosciences
TYRA
|
+$1.19M |
| 5 |
JBIO
Jade Biosciences
JBIO
|
+$1.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$2.57M |
| 2 |
Revolution Medicines
RVMD
|
+$2.56M |
| 3 |
State Street
STT
|
+$2.11M |
| 4 |
Autohome
ATHM
|
+$2.11M |
| 5 |
Cal-Maine
CALM
|
+$1.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.7% |
| 2 | Technology | 15.71% |
| 3 | Financials | 9.07% |
| 4 | Communication Services | 7.06% |
| 5 | Consumer Discretionary | 5.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apple
AAPL
$4.79T
| $2.15M | 2.06% |
+7,445
| New | +$2.13M |
|
|
BLTE
2
Belite Bio
BLTE
$6.89B
| $2.12M | 2.03% |
13,758
-55
| -0.4% | -$8.43K |
|
3
Acadia Pharmaceuticals
ACAD
$4.8B
| $2.09M | 2% |
82,629
+14,339
| +21% | +$315K |
|
4
Comcast
CMCSA
$94.6B
| $2.08M | 1.99% |
84,569
+43,020
| +104% | +$1.11M |
|
|
CLDT
5
Chatham Lodging
CLDT
$605M
| $1.85M | 1.77% |
140,000
| – | – |
|
6
Tenax Therapeutics
TENX
$66.6M
| $1.79M | 1.72% |
123,174
+27,844
| +29% | +$356K |
|
|
SLDE
7
Slide Insurance Holdings
SLDE
$2.89B
| $1.76M | 1.69% |
91,070
+60,412
| +197% | +$1.09M |
|
8
Zymeworks
ZYME
$2.14B
| $1.74M | 1.67% |
66,688
-16,010
| -19% | -$407K |
|
9
AMN Healthcare
AMN
$1.29B
| $1.68M | 1.61% |
51,906
+1,906
| +4% | +$49.2K |
|
|
10
X4 Pharmaceuticals
XFOR
$401M
| $1.64M | 1.57% |
+352,093
| New | +$1.44M |
|
|
VSNT
11
Versant Media Group
VSNT
$5.7B
| $1.57M | 1.5% |
43,503
+24,506
| +129% | +$984K |
|
12
NETSCOUT
NTCT
$2.73B
| $1.44M | 1.38% |
33,128
+18,406
| +125% | +$693K |
|
|
WHWK
13
Whitehawk Therapeutics
WHWK
$264M
| $1.38M | 1.32% |
301,483
+185,999
| +161% | +$774K |
|
14
Johnson & Johnson
JNJ
$671B
| $1.37M | 1.31% |
5,384
-34
| -0.6% | -$7.92K |
|
|
CTNM
15
Contineum Therapeutics
CTNM
$661M
| $1.33M | 1.27% |
81,014
-5,018
| -6% | -$65.8K |
|
|
JBIO
16
Jade Biosciences
JBIO
$1.26B
| $1.25M | 1.2% |
+56,384
| New | +$1.18M |
|
17
Cisco
CSCO
$428B
| $1.21M | 1.16% |
+10,307
| New | +$1.08M |
|
18
Nurix Therapeutics
NRIX
$2.63B
| $1.2M | 1.15% |
49,511
-33,914
| -41% | -$578K |
|
|
19
Protara Therapeutics
TARA
$235M
| $1.19M | 1.14% |
+312,249
| New | +$1.49M |
|
20
Bloomin' Brands
BLMN
$833M
| $1.19M | 1.14% |
130,000
+30,000
| +30% | +$218K |
|
|
21
Tyra Biosciences
TYRA
$1.48B
| $1.15M | 1.1% |
+36,003
| New | +$1.19M |
|
22
Par Pacific Holdings
PARR
$4.11B
| $1.12M | 1.07% |
20,000
-2,500
| -11% | -$149K |
|
23
Edgewise Therapeutics
EWTX
$4.56B
| $1.11M | 1.06% |
27,234
+14,182
| +109% | +$489K |
|
24
Alphabet (Google) Class A
GOOGL
$4.19T
| $1.04M | 0.99% |
+2,900
| New | +$1.04M |
|
25
Carter's
CRI
$1.22B
| $1.03M | 0.99% |
25,000
| – | – |
|
Similar funds
IAP
JRSI
SFG
TPW
ACM
TOTUOP
XFP
ICVCFVA
Verdad Advisers's Q2 2026 Portfolio in Review
As of Q2 2026, Verdad Advisers held 276 positions worth $104M, up 18% from $88.8M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Verdad Advisers deployed $3.28M of net new capital in Q2 2026, opening 97 new positions and adding to 59 existing holdings. Its largest new stake was Apple: 7,445 shares worth $2.15M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 42% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Micron Technology, an estimated $2.57M trimmed.
- Verdad Advisers's largest Q2 2026 buy was Apple: 7,445 shares worth $2.15M.
- Verdad Advisers added most to Comcast in Q2 2026, an estimated $1.11M increase.
- Verdad Advisers's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $2.57M.
- Verdad Advisers fully exited State Street in Q2 2026, selling an estimated $2.11M.
- Verdad Advisers's ten largest holdings make up 18% of its $104M portfolio in Q2 2026.
- Verdad Advisers opened 97 new positions and closed 66 in Q2 2026.
- Verdad Advisers's portfolio value rose 18% quarter-over-quarter to $104M.
Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.